Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/taylor-francis/respirable-antisense-oligonucleotides-as-novel-therapeutic-agents-for-yPJLVsf0e1
References (29)
-
S. Devereux, F. Cotter (1996)
Anti-sense and gene therapy approaches to the treatment of lymphomas.Bailliere's clinical haematology, 9 4
-
R. Wagner, W. Flanagan (1997)
Antisense technology and prospects for therapy of viral infections and cancer.Molecular medicine today, 3 1
-
Jonathan Nyce, W. Metzger (1997)
DNA antisense therapy for asthma in an animal modelNature, 385
-
A. Kamada, S. Szefler, R. Martin, H. Boushey, V. Chinchilli, J. Drazen, J. Fish, E. Israel, S. Lazarus, R. Lemanske (1996)
Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network.American journal of respiratory and critical care medicine, 153 6 Pt 1
-
K. rd, Giles Re (1993)
Status of leukotriene antagonists and other modulators of lipid mediators.Agents and actions, 41
-
Bruno Bordier, MARiTrA PERALA-HEAPE, Genevieve DEGOLSt, Bernard LEBLEUt, Simon Litvak, Leila, SARIH-COTrrIN, Claude HEILENEt (1995)
Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells.Proceedings of the National Academy of Sciences of the United States of America, 92 20
-
M. Church, S. Holgate (1988)
Adenosine in asthmatic lung.Progress in clinical and biological research, 263
-
W. Hall, Eric Flores, W. Low (1996)
Antisense oligonucleotides for central nervous system tumors.Neurosurgery, 38 2
-
P. Barnes, B. Jônsson, JB Klim (1996)
The costs of asthma.The European respiratory journal, 9 4
-
Sudhir Agrawal (1996)
Antisense oligonucleotides: towards clinical trials.Trends in biotechnology, 14 10
-
J. Coulson, D. Poyner, A. Chantry, W. Irwin, S. Akhtar (1996)
A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.Molecular pharmacology, 50 2
-
M. Collis, S. Hourani (1993)
Adenosine receptor subtypes.Trends in pharmacological sciences, 14 10
-
W. Lima, V. Brown-Driver, M. Fox, R. Hanecak, T. Bruice (1997)
Combinatorial Screening and Rational Optimization for Hybridization to Folded Hepatitis C Virus RNA of Oligonucleotides with Biological Antisense Activity*The Journal of Biological Chemistry, 272
-
S. Lanes, B. Birmann, D. Raiford, A. Walker (1997)
International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992.Journal of clinical epidemiology, 50 3
-
I. Jääskeläinen, J. Mönkkönen, A. Urtti (1994)
Oligonucleotide-cationic liposome interactions. A physicochemical study.Biochimica et biophysica acta, 1195 1
-
L. Lima, G. Prat-Gay (1997)
Conformational Changes and Stabilization Induced by Ligand Binding in the DNA-binding Domain of the E2 Protein from Human Papillomavirus*The Journal of Biological Chemistry, 272
-
R. Morishita, Gary Gibbons, Y. Kaneda, T. Ogihara, Victor Dzau (1994)
Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.Gene, 149 1
-
S. Agrawal (1997)
Dollars and AntisenseSciences-new York, 37
-
S. Suissa, B. Hemmelgarn, L. Blais, P. Ernst (1996)
Bronchodilators and acute cardiac death.American journal of respiratory and critical care medicine, 154 6 Pt 1
-
A. Branch (1996)
A Hitchhiker's guide to antisense and nonantisense biochemical pathwaysHepatology, 24
-
T. Björck, Lars Gustafsson, S. Dahlén (1992)
Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine.The American review of respiratory disease, 145 5
-
P. Ind (1996)
Anti-leukotriene intervention: is there adequate information for clinical use in asthma?Respiratory medicine, 90 10
-
M. Neurath, S. Pettersson, K. Büschenfelde, W. Strober (1996)
Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in miceNature Medicine, 2
-
M. Seki, Y. Honda (1995)
Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay.Journal of biochemistry, 118 6
-
T. Giangrasso (1997)
Potential for tolerance, morbidity, and mortality resulting from regular use of beta 2-adrenergic agonists in asthma.Southern medical journal, 90 2
-
M. Phillips, D. Wielbo, R. Gyurko (1994)
Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genesKidney International, 46
-
Matherne Gp, Byford Am, Gilrain Jt, Dalkin Ac (1996)
Changes in myocardial A1 adenosine receptor and message levels during fetal development and postnatal maturation.Neonatology, 70
-
R. Djukanović, S. Homeyard, C. Gratziou, J. Madden, A. Walls, S. Montefort, D. Peroni, R. Polosa, S. Holgate, P. Howarth (1997)
The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation.American journal of respiratory and critical care medicine, 155 3
-
D. Robertson (1997)
Crohn's trial shows the pros of antisenseNature Biotechnology, 15
- Publisher
- Taylor & Francis
- Copyright
- © 1997 Ashley Publications Ltd.
- ISSN
- 1744-7658
- eISSN
- 1354-3784
- DOI
- 10.1517/13543784.6.9.1149
- Publisher site
- See Article on Publisher Site
Abstract
Respirable antisense oligonucleotides (rAsONs) targeting discordantly expressed mediators of inflammation and/or bronchoconstriction and delivered to the lung via inhalation represent a new class of epigenetic-based therapeutics for asthma and other pulmonary diseases. The properties of these agents (solubility, chemical stability, rapid design based on primary DNA sequence information) combine synergistically with characteristics of the lung (non-invasive route of administration directly to the target organ, presence of uptake-modifying surfactant) to enhance the therapeutic potential of these oligonucleotide-based drugs. Their potential is further increased by the possibility of engineering antisense oligonucleotides whose effects are limited to the lung, reducing or avoiding the possibility of systemic toxicity.
Journal
Expert Opinion on Investigational Drugs – Taylor & Francis
Published: Sep 1, 1997
Keywords: antisense; asthma; chronic bronchitis; chronic obstructive pulmonary disease; cystic fibrosis; epigenetics; oligonucleotide therapeutics; pulmonary; pulmonary hypertension